Urticaria updates from ACAAI 2025 include data on dupilumab for chronic urticaria, the relative effectiveness of 55 ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 74.3% of children had an allergic asthma phenotype.

In this real world cohort, tralokinumab for dupilumab nonresponders reduced body surface area and pruritus scores and eased flares, supporting its role in difficult atopic dermatitis.

Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life ...

Atopic / dry skin / dermatitis image of children Children with atopic dermatitis who were treated with dupilumab and topical corticosteroids showed improvements in treatment success compared with ...

Credit: Getty Images. Treatment with dupilumab led to a significant 30% reduction in moderate or severe acute COPD exacerbations. Dupilumab was found to significantly reduce exacerbations in adults ...

Please provide your email address to receive an email when new articles are posted on . Serum dupilumab levels showed no correlation to treatment response or adverse events in patients with atopic ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...